APA

Lam S. W., de Groot S. M., Honkoop A. H., Jager A., ten Tije A. J., Bos M. M. E. M., Linn S. C., van den Bosch J., Kroep J. R., Braun J. J., van Tinteren H. & Boven E. (20150127). Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial. : European journal of cancer (Oxford, England : 1990).

Chicago

Lam S W, de Groot S M, Honkoop A H, Jager A, ten Tije A J, Bos M M E M, Linn S C, van den Bosch J, Kroep J R, Braun J J, van Tinteren H and Boven E. 20150127. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial. : European journal of cancer (Oxford, England : 1990).

Harvard

Lam S. W., de Groot S. M., Honkoop A. H., Jager A., ten Tije A. J., Bos M. M. E. M., Linn S. C., van den Bosch J., Kroep J. R., Braun J. J., van Tinteren H. and Boven E. (20150127). Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial. : European journal of cancer (Oxford, England : 1990).

MLA

Lam S W, de Groot S M, Honkoop A H, Jager A, ten Tije A J, Bos M M E M, Linn S C, van den Bosch J, Kroep J R, Braun J J, van Tinteren H and Boven E. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial. : European journal of cancer (Oxford, England : 1990). 20150127.